Los puntos clave no están disponibles para este artículo en este momento.
Abstract Vaccines based on mRNA technology have been tremendously successful, but their properties are not necessarily ideal for all pathogens. There is a risk that concentration on that technology alone for new vaccine development will ignore older technologies that have properties giving broader and more persistent protection.
Plotkin et al. (Fri,) studied this question.